+0.04 (+1.68%)
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
XTL Biopharmaceuticals Ltd. has received a delisting notice from Nasdaq due to its failure to file the Annual Report for 2025. The company is already under review for not meeting minimum equity and bid price requirements. XTL intends to request an extension for the suspension of its securities by May 26, 2026, but faces uncertainty regarding the Panel's decision.
Read more →XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio, effective March 25, 2026. The new ratio will be one ADS for every 400 ordinary shares, resulting in a reverse split. This change aims to increase the trading price of ADSs, although no guarantees are provided. No fees will be incurred by ADS holders during this process.
Read more →XTL Biopharmaceuticals Ltd. has received a delisting determination from Nasdaq due to its classification as a 'public shell.' The company plans to appeal this decision through a hearing, which will temporarily halt the delisting process. The Nasdaq Staff cited the company's lack of an operating business and failure to meet financial requirements as reasons for the delisting.
Read more →XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc. after signing a Binding Letter of Intent. A shareholders meeting is set for February 17, 2026, to discuss a private placement aimed at addressing compliance with Nasdaq's equity requirements. However, there are uncertainties regarding the acquisition's completion and shareholder approval.
Read more →XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the minimum stockholders' equity requirement for continued listing. The company reported a deficit of $47,000 in its equity. XTL has 45 days to submit a plan to regain compliance, and it is currently evaluating options to address this issue.
Read more →XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a company focusing on disease-modifying therapies for Autism Spectrum Disorder. This strategic move aims to address the critical unmet medical need for autism treatments, as no FDA-approved options currently exist. The acquisition includes a team of Nobel Laureates and secured FDA Orphan Drug designations for related conditions, signaling a strong commitment to advancing autism therapeutics.
Read more →XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer. Band brings significant experience from his previous roles in technology and digital marketing. His leadership is expected to drive the company towards new opportunities and enhance operational excellence. The Board expresses confidence in his ability to contribute to the company's growth.
Read more →XTL Biopharmaceuticals Ltd. has completed the acquisition of The Social Proxy, an AI web data company, enhancing its IP portfolio. The transaction involved a private placement of $1.5 million, allowing XTL to support Social Proxy's growth. Social Proxy will operate as a wholly owned subsidiary, with its shareholders joining XTL's board of directors.
Read more →XTL Biopharmaceuticals Ltd. has entered into a definitive agreement to acquire The Social Proxy, an AI web data company. The acquisition involves a private placement that will give The Social Proxy's shareholders a significant stake in XTL. This move is part of XTL's strategy to enhance its asset portfolio in high-growth markets. The transaction is contingent on customary approvals and conditions.
Read more →XTL Biopharmaceuticals Ltd. has announced a binding term sheet to acquire The Social Proxy, a web data AI company. The acquisition will involve issuing shares representing 44.6% of XTL's outstanding capital and a payment of $430,000. The deal aims to enhance XTL's asset portfolio in the high-growth AI web data market. The transaction is contingent upon several conditions, including shareholder approval.
Read more →XTL Biopharmaceuticals has received a notification from Nasdaq regarding a deficiency in its minimum bid price, which must be $1.00 per share. The company has 180 days to regain compliance, or it may face delisting. XTL plans to monitor its stock price and explore options to meet Nasdaq's requirements.
Read more →XTL Biopharmaceuticals Ltd. has confirmed that its operations in Israel remain unaffected by recent events, including a terrorist attack and the declaration of war. The company continues its normal activities and is closely monitoring the situation to ensure business continuity. CEO Shlomo Shalev reassured partners and shareholders of the company's stable operations.
Read more →